Device Trial Radar · NCT04362774
ORBERA365 Post-Marketing Clinical Follow-up Study
Last checked: Nov 20, 2026Latest source record: Dec 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
25
Actual
Start
Feb 23, 2021
Primary completion
Feb 21, 2023
Study completion Oct 10, 2023
Sponsor
- Lead sponsor
- Apollo Endosurgery, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 27, 2020
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, multicenter, open-label, post-approval study of the safety and effectiveness of ORBERA36 as a 12-month adjunct to weight reduction for obese adults (BMI ≥ 27 kg/m2 and BMI ≤ 50 kg/m2) or for pre-surgical weight reduction in obese and super-obese adults (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities).
Conditions
- Obesity
- Overweight
Interventions
ORBERA365Device
Behavioral modification program in conjunction with endoscopic placement of a single ORBERA365 Intragastric Balloon, filled with saline to an inflation volume between 400cc and 700cc with 2mL of Methylene blue (10mg/mL)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Early Removal PercentTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Obymed
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.